Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07102043 · ClinicalTrials.gov registry record
Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)
A clinical trial, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 30
- Enrollment target
NCT07102043 is a clinical trial that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants.
The verdict
NCT07102043 is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
Study Summary
The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR modulator (ETI) therapy (CFRDF508del+ETI). CFRD with a mutation that is not eligible for modulator therapy (CFRD-ETI) will be the control group.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2028-05-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07102043
The ClinicalTrials.gov registry entry for NCT07102043 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT07102043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07102043 about?
NCT07102043 is a clinical study titled "Glucose Metabolism in Cystic Fibrosis Related Diabetes (CFRD)". The study aims to test whether use of CFTR modulators (ETI) improves fasting and post prandial glycemia by enhancing disposition index (DI) in individuals with CFRD with CFTR +ve mutation (at least one copy of F508del) on CFTR modulator (ETI) therapy (CFRDF508del+ETI). CFRD with a mutation that is n...
What is the current status of trial NCT07102043?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2026-05-28. Estimated completion is 2028-05-28.
Who is sponsoring clinical trial NCT07102043?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.